• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Number of biosimilar biological product development (BPD) Type 1-4 meeting requests received in the month

Dictionary: Biosimilar biological product development (BPD) meeting refers to any meeting, other than a biosimilar initial advisory meeting, regarding the content of a development program, including a proposed design for, or data from, a study intended to support a biosimilar biological product application.

Information is current as of December 31, 2014.

Fiscal Year - 2015

Skip graphic and jump to text data

TimeTargetNumber
Oct 2014N/A5
Nov 2014N/A5
Dec 2014N/A6
Jan 2015N/ATBD
Feb 2015N/ATBD
Mar 2015N/ATBD
Apr 2015N/ATBD
May 2015N/ATBD
Jun 2015N/ATBD
Jul 2015N/ATBD
Aug 2015N/ATBD
Sep 2015N/ATBD

FY 2015 YTD: 16

Footnotes

  • CDER began collecting data for the these measures in January 2013.

Number of biosimilar biological product development (BPD) Type 1-4 meetings held in the month

Fiscal Year - 2015
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2014N/A8
Nov 2014N/A3
Dec 2014N/A5
Jan 2015N/ATBD
Feb 2015N/ATBD
Mar 2015N/ATBD
Apr 2015N/ATBD
May 2015N/ATBD
Jun 2015N/ATBD
Jul 2015N/ATBD
Aug 2015N/ATBD
Sep 2015N/ATBD

FY 2015 YTD: 16

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.